Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies (RECIPE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03864185
Recruitment Status : Active, not recruiting
First Posted : March 6, 2019
Last Update Posted : June 4, 2020
Sponsor:
Collaborators:
Japan Agency for Medical Research and Development
Zenyaku Kogyo Co., Ltd.
Information provided by (Responsible Party):
Masahiro Iijima, Nagoya University

Tracking Information
First Submitted Date  ICMJE February 19, 2019
First Posted Date  ICMJE March 6, 2019
Last Update Posted Date June 4, 2020
Actual Study Start Date  ICMJE March 28, 2019
Estimated Primary Completion Date September 30, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 8, 2019)
Rate of patients with improvement in adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale [ Time Frame: Up to 52 weeks ]
Primary analysis will compare scores of adjusted INCAT Disability Scale evaluated prior to treatment (at the time of enrollment) and scores at each timepoint after week 26 to calculate the proportion of patients who achieve an improvement of one and more from the baseline. The INCAT Disability Scale is an index to evaluate disorders in lower (gait) and upper (elevation of the upper arms and fine movement of the fingertips) extremities. The INCAT score is a 10-point scale and ranges from 0 (normal) to 10 (worst). For the "adjusted" INCAT score, a change in upper extremity score from 0 to 1 or 1 to 0 will not be considered meaningful in this evaluation.
Original Primary Outcome Measures  ICMJE
 (submitted: March 3, 2019)
Rate of patients with improvement in adjusted INCAT disability scale [ Time Frame: Up to 52 weeks ]
Primary analysis will compare scores of adjusted INCAT Disability Scale evaluated prior to treatment (at the time of enrollment) and scores at each timepoint after week 26 to calculate the proportion of patients who achieve an improvement of one and more from the baseline.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: March 8, 2019)
  • Change in grip strength (kPa) [ Time Frame: Up to 52 weeks ]
    The differences of Grip strength (kPa) between prior to treatment and at each timepoint are summarized.
  • Change in Rasch-built Overall Disability Scale (R-ODS) score [ Time Frame: Up to 52 weeks ]
    The differences of R-ODS score between prior to treatment and at each timepoint are summarized. R-ODS is consist of a 24-item questionnaire about daily living task with 3 response options: (0) "impossible to perform," (1) "performed with difficulty," and (2) "easily performed. The R-ODS score is a 48-point scale (range: 0-48), and is converted into a centile metric score with values ranging from 0 (most severe activity and social participation limitations) to 100 (no activity and social participation limitations).
  • Change in Medical Research Council (MRC) Sum Score [ Time Frame: Up to 52 weeks ]
    The differences of MRC Sum Score between prior to treatment and at each timepoint are summarized. The MRC Sum Score is a scale to assess for 8 muscle groups (right and left side) as follow: Shoulder abduction, Elbow flexion, Wrist extension, Index finger abduction, Hip flexion, Knee extension, Foot dorsiflexion, Great toe dorsiflexion.The MRC Sum Score is a 80-point scale and ranges from 0 (paralysis) to 80 (normal strength).
  • Change in motor nerve distal latency [ Time Frame: Up to 52 weeks ]
    The differences of distal latency between prior to treatment and at each timepoint are summarized.
  • Change in motor nerve proximal latency [ Time Frame: Up to 52 weeks ]
    The differences of proximal latency between prior to treatment and at each timepoint are summarized.
  • Change in motor nerve compound muscle action potential (CMAP) [ Time Frame: Up to 52 weeks ]
    The differences of CMAP between prior to treatment and at each timepoint are summarized.
  • Change in motor nerve conduction velocity [ Time Frame: Up to 52 weeks ]
    The differences of motor nerve conduction velocity between prior to treatment and at each timepoint are summarized.
  • Cerebrospinal fluid protein level [ Time Frame: Up to 52 weeks ]
    Cerebrospinal fluid protein level at each timepoint are summarized.
  • B cell counts (CD19 positive and CD20 positive cell counts) and T cell counts (CD3 positive, CD4 positive, and CD8 positive cell counts) [ Time Frame: Up to 52 weeks ]
    B cell counts (CD19 positive and CD20 positive cell counts) and T cell counts (CD3 positive, CD4 positive, and CD8 positive cell counts) at each timepoint are summarized.
  • Expression of HACA [ Time Frame: Up to 52 weeks ]
    The number of patients expressing HACA, and the proportion and its 95% confidence interval of these patients at each timepoint are summarized.
  • Serum rituximab (genetical recombination) level [ Time Frame: Up to 52 weeks ]
    Serum rituximab (genetical recombination) level at each timepoint are summarized.
  • Maximum serum concentration (Cmax) of rituximab (genetical recombination) [ Time Frame: Up to 52 weeks ]
    Cmax of rituximab (genetical recombination) is summarized.
  • Area under the curve (AUC) of blood concentration of rituximab (genetical recombination) [ Time Frame: Up to 52 weeks ]
    AUC of blood concentration of rituximab (genetical recombination) is summarized.
  • Half-life (t1/2) of rituximab (genetical recombination) [ Time Frame: Up to 52 weeks ]
    t1/2 of rituximab (genetical recombination) is summarized.
  • Clearance (CL) of rituximab (genetical recombination) [ Time Frame: Up to 52 weeks ]
    CL of rituximab (genetical recombination) is summarized.
  • Mean residence time (MRT) of rituximab (genetical recombination) [ Time Frame: Up to 52 weeks ]
    MRT of rituximab (genetical recombination) is summarized.
  • Volume of distribution (Vds) of rituximab (genetical recombination) level [ Time Frame: Up to 52 weeks ]
    Vds of rituximab (genetical recombination) is summarized.
  • Serum antibody titers of IgG4 (CNTN-1 and NF-155) and these IgG subclass [ Time Frame: Up to 52 weeks ]
    Serum titers (CNTN-1 and NF-155, and these IgG subclasses 1 to 4) at each timepoint are summarized.
  • Serum neurofilament [ Time Frame: Up to 52 weeks ]
    Serum neurofilament level at each timepoint is summarized.
Original Secondary Outcome Measures  ICMJE
 (submitted: March 3, 2019)
  • Change in grip strength (kPa) [ Time Frame: Up to 52 weeks ]
    The differences of Grip strength (kPa) between prior to treatment and at each timepoint are summarized.
  • Change in Rasch-built Overall Disability Scale (R-ODS) score [ Time Frame: Up to 52 weeks ]
    The differences of R-ODS score between prior to treatment and at each timepoint are summarized.
  • Change in Medical Research Council (MRC) Sum Score [ Time Frame: Up to 52 weeks ]
    The differences of MRC Sum Score between prior to treatment and at each timepoint are summarized.
  • Change in motor nerve distal latency [ Time Frame: Up to 52 weeks ]
    The differences of distal latency between prior to treatment and at each timepoint are summarized.
  • Change in motor nerve proximal latency [ Time Frame: Up to 52 weeks ]
    The differences of proximal latency between prior to treatment and at each timepoint are summarized.
  • Change in motor nerve compound muscle action potential (CMAP) [ Time Frame: Up to 52 weeks ]
    The differences of CMAP between prior to treatment and at each timepoint are summarized.
  • Change in motor nerve conduction velocity [ Time Frame: Up to 52 weeks ]
    The differences of motor nerve conduction velocity between prior to treatment and at each timepoint are summarized.
  • Cerebrospinal fluid protein level [ Time Frame: Up to 52 weeks ]
    Cerebrospinal fluid protein level at each timepoint are summarized.
  • B cell counts (CD19 positive and CD20 positive cell counts) and T cell counts (CD3 positive, CD4 positive, and CD8 positive cell counts) [ Time Frame: Up to 52 weeks ]
    B cell counts (CD19 positive and CD20 positive cell counts) and T cell counts (CD3 positive, CD4 positive, and CD8 positive cell counts) at each timepoint are summarized.
  • Expression of HACA [ Time Frame: Up to 52 weeks ]
    The number of patients expressing HACA, and the proportion and its 95% confidence interval of these patients at each timepoint are summarized.
  • Serum rituximab (genetical recombination) level [ Time Frame: Up to 52 weeks ]
    Serum rituximab (genetical recombination) level at each timepoint are summarized.
  • Maximum serum concentration (Cmax) of rituximab (genetical recombination) [ Time Frame: Up to 52 weeks ]
    Cmax of rituximab (genetical recombination) is summarized.
  • Area under the curve (AUC) of blood concentration of rituximab (genetical recombination) [ Time Frame: Up to 52 weeks ]
    AUC of blood concentration of rituximab (genetical recombination) is summarized.
  • Half-life (t1/2) of rituximab (genetical recombination) [ Time Frame: Up to 52 weeks ]
    t1/2 of rituximab (genetical recombination) is summarized.
  • Clearance (CL) of rituximab (genetical recombination) [ Time Frame: Up to 52 weeks ]
    CL of rituximab (genetical recombination) is summarized.
  • Mean residence time (MRT) of rituximab (genetical recombination) [ Time Frame: Up to 52 weeks ]
    MRT of rituximab (genetical recombination) is summarized.
  • Volume of distribution (Vds) of rituximab (genetical recombination) level [ Time Frame: Up to 52 weeks ]
    Vds of rituximab (genetical recombination) is summarized.
  • Serum antibody titers of IgG4 (CNTN-1 and NF-155) and these IgG subclass [ Time Frame: Up to 52 weeks ]
    Serum titers (CNTN-1 and NF-155, and these IgG subclasses 1 to 4) at each timepoint are summarized.
  • Serum neurofilament [ Time Frame: Up to 52 weeks ]
    Serum neurofilament level at each timepoint is summarized.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies
Official Title  ICMJE The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients With Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical Trial
Brief Summary To evaluate the efficacy and safety of rituximab (genetical recombination) intravenously administered to CIDP patients with positive or negative IgG4 autoantibody.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Intervention  ICMJE
  • Biological: Rituximab (genetical recombination)
    Administer 375 mg/m2 of rituximab (genetical recombination) IV infusion once weekly for 4 doses.
  • Other: Placebo
    Administer placebo IV infusion once weekly for 4 doses.
Study Arms  ICMJE
  • Active Comparator: Rituximab group (IgG4 autoantibody positive)
    Intervention: Biological: Rituximab (genetical recombination)
  • Placebo Comparator: Placebo group (IgG4 autoantibody positive)
    Intervention: Other: Placebo
  • Active Comparator: Rituximab group (IgG4 autoantibody negative)
    Intervention: Biological: Rituximab (genetical recombination)
Publications * Shimizu S, Iijima M, Fukami Y, Tamura N, Nakatochi M, Ando M, Nishi R, Koike H, Kaida K, Koga M, Kanda T, Ogata H, Kira JI, Mori M, Kuwabara S, Katsuno M. Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial. JMIR Res Protoc. 2020 Apr 1;9(4):e17117. doi: 10.2196/17117.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: March 3, 2019)
25
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE September 30, 2021
Estimated Primary Completion Date September 30, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Patients with definite CIDP diagnosed according to the modified diagnostic criteria of European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) (2010) by the time of enrollment in the study
  2. Patients meeting one of the following conditions:

    (i) Patients with positive serum IgG4 autoantibody (CNTN-1 or NF-155) confirmed by the time of enrollment in the study

    (ii) Patients with negative serum IgG4 autoantibody (CNTN-1 and NF-155) confirmed by the time of enrollment in the study

  3. Patients with refractory CIDP not responding adequately to treatment with corticosteroid for 12 weeks, and intravenous immunoglobulin therapy (IVIg) for 8 weeks by the time of enrollment in the study, or those who are unable to administer or continue corticosteroid and IVIg
  4. Patients with total adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale scores of 2 to 8 at both preliminary enrollment and enrollment, and with the total score at enrollment equal to or worse than that at preliminary enrollment
  5. Patients aged 12 years or older at informed consent
  6. Patients who give their voluntary written consent after having received adequate information on this study (legally acceptable representatives should also give consent for underage patients, and informed assent should be obtained from children aged 12 to 15)

Exclusion Criteria:

  1. Patients with disease meeting one of the following exclusion criteria defined in the modified EFNS/PNS diagnostic criteria (2010).

    (i) Borrelia burgdorferi infection (Lyme disease), diphtheria, drug or toxin exposure probably to have caused the neuropathy Hereditary demyelinating neuropathy

    (ii) Prominent sphincter disturbance

    (iii) Diagnosis of multifocal motor neuropathy

    (iv) IgM monoclonal gammopathy with high titre antibodies to myelin-associated glycoprotein

    (v) Other causes for a demyelinating neuropathy including POEMS syndrome, osteosclerotic myeloma, diabetic and non-diabetic lumbosacral radiculoplexus neuropathy PNS lymphoma and amyloidosis may occasionally have demyelinating features

  2. Patients who have started or have increased the dose of corticosteroid for CIDP within 12 weeks prior to the enrollment
  3. Patients who have started or have increased the dose of IVIg within 8 weeks prior to the enrollment
  4. Patients who have underwent plasmapheresis within 8 weeks prior to the enrollment or patients with refractory disease not responding adequately to 8 weeks of plasmapheresis (plasma exchange or double-filtration plasmapheresis)
  5. Patients who have started or have increased the dose of an immunosuppressant (azathioprine, cyclophosphamide, cyclosporine, mycophenolate mofetil, interferon alpha, interferon beta, etanercept, methotrexate, mitoxantrone, alemtuzumab, cladribine, tacrolimus, fingolimod) within 12 weeks prior to the enrollment
  6. Patients who have underwent hematopoietic stem cell transplant prior to the enrollment
  7. Patients who have used rituximab (genetical recombination) prior to the enrollment
  8. Patients who have participated in another clinical study within 3 months prior to the enrollment (enrollment is allowed for those participating in a clinical study in the range of Indications or Dosage and Administration in Japan) or patients who are participating in another study
  9. Patients with poorly controlled diabetes (HbA1c of 7 % or higher)
  10. Patients who have or are suspected to have active infection (infection requiring treatment with systemic antimicrobial, antifungal, or antiviral agents) at the time of the enrollment
  11. Patients tested positive for HBs antigen, HBs antibody, HBc antibody, and/or HCV antibody (patients with positive HBs antibody or HBc antibody can be enrolled when a hepatitis B virus-DNA test is negative [below the limit of detection], and hepatitis B virus-DNA and aspartate/alanine transaminase levels are monitored at fixed intervals), or patients with positive HIV antibody or HTLV-1 antibody at the time of the enrollment
  12. Patients with leukopenia (less than 2,000 /mm3), neutropenia (less than 1,000 /mm3), or lymphopenia (less than 500 /mm3) at the time of the enrollment
  13. Patients with history of serious hypersensitivity or anaphylactic reaction to one of the ingredients in the investigational drug or murine protein-containing products
  14. Patients with serious comorbidity (e.g., hepatic, renal, cardiac, lung, hematologic, or brain disease)
  15. Female patients who are pregnant, lactating, or potentially pregnant, or patients who are not willing to use contraceptive measures during the study period
  16. Patients who are judged to be unsuitable by the investigator or a sub-investigator
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 12 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Japan
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03864185
Other Study ID Numbers  ICMJE CAMCR-011
jRCT2041180037 ( Registry Identifier: Japan Registry of Clinical Tials )
UMIN000035753 ( Registry Identifier: UMIN Clinical Trials Registry )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Masahiro Iijima, Nagoya University
Study Sponsor  ICMJE Nagoya University
Collaborators  ICMJE
  • Japan Agency for Medical Research and Development
  • Zenyaku Kogyo Co., Ltd.
Investigators  ICMJE
Principal Investigator: Masahiro Iijima, Ph. D Nagoya University Hospital
PRS Account Nagoya University
Verification Date June 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP